AYUR-VEDA BIO-DEVELOPMENT LIMITED COMPANY
Update：2026/08/06
Industries
Main Industry
Consumer Goods
Main Product/Service
OBI Pharma’s product and technology portfolio focuses on antibody-drug conjugates (ADCs) and enabling platforms. Core proprietary technologies include GlycOBI® glycan-conjugation platform, EndoSymeOBI®, ThiOBI®, HYPrOBI™, which enable plug-and-play compat
Founded Year
2018
Unified Business No.
50775252
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBI Pharma, Inc., founded in 2002 with its headquarters and R&D center in Taiwan, and subsidiaries in the United States and Australia, is a global clinical-stage oncology company. The company focuses on innovative cancer therapies, aiming to develop first-in-class and best-in-class drugs under the “Made in Taiwan” branding, and to deliver new treatment options to patients with unmet medical needs worldwide.
